Clinical Ink's mobile patient engagement platform called CentrosHealth has been updated to integrate with Qualcomm Life's 2net Mobile Platform and include connectivity for a wide range of medical devices. The company's new solution was developed with cooperation from Novartis and PPD, global leaders in pharmaceuticals and clinical research, who are also supporting a pilot clinical study before broad commercial use.
"CentrosHealth delivers a true patient-centric experience by capturing real-time medical device data directly through an app running on a patient's own cell phone," comments Ed Seguine, CEO, Clinical Ink. "Working with PPD and Novartis to accomplish this 'light-weight' approach to capturing device data from patients as part of their normal daily activity has the potential to make study participation more convenient for patients while reducing costs and implementation challenges."
The CentrosHealth platform supports creation of trial-specific mobile apps designed to personalize the patient experience during a clinical trial.The CentrosHealth platform supports creation of trial-specific mobile apps designed to personalize the patient experience during a clinical trial, expand the frequency and breadth of participant data collection, and enhance participant engagement and compliance. The technology offers trial teams continuous insight into the patient trial experience, while supplying enhanced information for results analysis.
When it comes to trial participants, they get to benefit from contextually-relevant educational content offerings as well as calendar-integrated reminders, SMS communications, email and more, keeping them [trial participants] involved, informed, compliant, and active throughout the process.
Qualcomm Life's 2net Platform and open medical device ecosystem enable simplified, scalable device deployments while ensuring medical grade health data integrity, security and privacy.